Skip to main content

Table 3 Adjusted likelihoods of receiving care concordant with the recommendations at a single visita

From: Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations

  MTX monotherapy users (n = 741) Multiple nbDMARD users (n = 995)
Patient factors
 High disease activity (vs. moderateb) 1.85 (1.29–2.66) 1.67 (1.23–2.26)
 Disease duration (per 5 years) 0.95 (0.87–1.05) 0.85 (0.79–0.91)
Provider factors
 Geographic region
  Northeast (reference) 1 1
  South 1.14 (0.63–2.07) 1.23 (0.86–1.77)
  Midwest 1.56 (0.82–2.97) 1.67 (1.18–2.37)
  West 1.92 (0.83–4.42) 1.06 (0.61–1.82)
Time period
 December 2008–November 2009 (reference) 1 1
 December 2009–November 2010 0.81 (0.52–1.28) 1.15 (0.82–1.62)
 December 2010–November 2011 1.09 (0.70–1.71) 0.86 (0.59–1.26)
 December 2011–February 2013 0.71 (0.42–1.19) 0.76 (0.50–1.14)
  1. aAdjusted for age, sex, work status, prednisone use, practice years, and time period, although none significantly associated as well as clustering of patients within physician. Patient race/ethnicity (white vs. black vs. Asian vs. other) was included in the models but could not be evaluated, owing to confounding of this characteristic by site
  2. bHigh disease activity was compared with moderate disease activity with a poor prognosis for the methotrexate (MTX) monotherapy users and moderate therapy without regard to prognosis for the multiple nonbiologic disease-modifying antirheumatic drug (nbDMARD) users